Preimplantation genetic diagnosis
is used for a broader range of indications, including chromosomal
abnormalities, genetic abnormalities associated with adult onset disorders,
rhesus incompatibility, human leukocyte antigens (HLA) tissue type, and
intentionally selecting for medical conditions (deafness) and traits like sex.
Statistics:
The global Preimplantation
Genetic Diagnosis Market is estimated to account for US$ 53.5 Mn in terms
of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.
Global Preimplantation Genetic
Diagnosis Market: Drivers
Rising rate of infertility is
expected to propel growth of the global preimplantation genetic diagnosis
market over the forecast period. For instance, according to the National Survey
of Family Growth data published in September 2018, 15.5% of all women who
intend to become pregnant are infertile and 6.7% of married women aged 15 to 44
years are infertile, in the U.S.
Global Preimplantation Genetic Diagnosis
Market: Opportunities
R&D in genetics is expected
to offer lucrative growth opportunities for players in the global
preimplantation genetic diagnosis market. People want to be guilt free from
giving the sufferings of genetic disorders to their children. Clinical progress
in the IVF and preimplantation genetic diagnosis and the increasing knowledge
in the medicine and molecular field associated with both male and female
infertility and that in intracytoplasmic sperm injection will assist in growth
of the global preimplantation genetic diagnosis market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/698
Global Preimplantation Genetic
Diagnosis Market: Restraints
Scientific, ethical, and policy
issues are expected to hinder growth of the global preimplantation genetic
diagnosis market. There are quite a few issues persistent about the safety of
the in vitro fertilization in preimplantation genetic diagnosis. The accuracy
of these methods is also questioned by a few physicians and researchers. In
addition, few people also find preimplantation genetic diagnosis as morally
unacceptable because of involvement of unnatural creation and destruction of
human embryo. There is a huge ethical issues regarding whether preimplantation
genetic diagnosis should be adopted or not.
Key Takeaways:
The global preimplantation
genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to
reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027.
Major factor driving the growth of global preimplantation genetic diagnosis
market during the forecast period include increasing incidences of genetic
diseases, and increasing number of fertility centers.
Chromosomal Abnormalities held
dominant position in the global preimplantation genetic diagnosis market in 2019,
accounting for 20.1% share in terms of value, followed by X-linked diseases and
Aneuploidy, respectively. Increasing prevalence of genetic disorders is supporting
growth of the segment.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/preimplantation-genetic-diagnosis-market-698
Market Trends
Major players in the global
preimplantation genetic diagnosis market are focused on adopting partnership
and collaboration strategies to enhance their market share. For instance, in
October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which
Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and
America.
Major players in the global
preimplantation genetic diagnosis market are also focused on adopting expansion
strategies to enhance their market share. For instance, in June 2020, Natera,
Inc. announced the expansion of its laboratory facility in Austin, Texas,
supporting greater test processing capacity.
Global Preimplantation Genetic
Diagnosis Market: Competitive Landscape
Major players operating in the
global preimplantation genetic diagnosis include, Amgen, Quest Diagnostics,
Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo
Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott
Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive
Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix
Corporation.
Global Preimplantation Genetic
Diagnosis Market: Key Developments
Major players in the global
preimplantation genetic diagnosis market are focused on adopting various
strategies to enhance their market share. For instance, in April 2019, Quest
Diagnostics presented new insights from genetic testing at the 2019 American
College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics
Meeting, held in the U.S.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/698
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-173
No comments:
Post a Comment